EBOV Mutation Detail Information

Virus Mutation EBOV Mutation A82V


Basic Characteristics of Mutations
Mutation Site A82V
Mutation Site Sentence The naturally occurring GP mutants A82V, A82V/T230A, and A82V/T230A/D637G were evaluated for their ability to infect cells by placing them in a mammalian expression plasmid containing the gene encoding EBOV Makona GP.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region GP
Standardized Encoding Gene GP
Genotype/Subtype Makona
Viral Reference KJ660346.2
Functional Impact and Mechanisms
Disease Cell line    
Immune -
Target Gene NPC1   
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location -
Literature Information
PMID 27814506
Title Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013-2016 Epidemic
Author Diehl WE,Lin AE,Grubaugh ND,Carvalho LM,Kim K,Kyawe PP,McCauley SM,Donnard E,Kucukural A,McDonel P,Schaffner SF,Garber M,Rambaut A,Andersen KG,Sabeti PC,Luban J
Journal Cell
Journal Info 2016 Nov 3;167(4):1088-1098
Abstract The magnitude of the 2013-2016 Ebola virus disease (EVD) epidemic enabled an unprecedented number of viral mutations to occur over successive human-to-human transmission events, increasing the probability that adaptation to the human host occurred during the outbreak. We investigated one nonsynonymous mutation, Ebola virus (EBOV) glycoprotein (GP) mutant A82V, for its effect on viral infectivity. This mutation, located at the NPC1-binding site on EBOV GP, occurred early in the 2013-2016 outbreak and rose to high frequency. We found that GP-A82V had heightened ability to infect primate cells, including human dendritic cells. The increased infectivity was restricted to cells that have primate-specific NPC1 sequences at the EBOV interface, suggesting that this mutation was indeed an adaptation to the human host. GP-A82V was associated with increased mortality, consistent with the hypothesis that the heightened intrinsic infectivity of GP-A82V contributed to disease severity during the EVD epidemic.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.